COMPASS Pathways plc Q3 2025 Earnings Recap

CMPS Q3 2025 November 5, 2025

Get alerts when CMPS reports next quarter

COMPASS Pathways reported significant progress in its Phase III trials for COMP360, with an accelerated NDA filing timeline now targeted for Q1 2026, positioning the company for potential market entry into treatment-resistant depression (TRD).

Earnings Per Share Beat

$-0.38 vs $-0.40 est.

+5.0% surprise

Market Reaction

1-Day -8.56%

5-Day -4.4%

30-Day -7.56%

See CMPS alongside your other holdings

Add to your portfolio — free

Key Takeaways

The completion of enrollment in the COMP006 trial enhances clarity for data readouts and regulatory timelines.
Positive discussions with the FDA support a rolling NDA submission strategy and a potential accelerated launch.
Cash reserves stand at $186 million, providing a runway into 2027, with disciplined spending amid ongoing operational expenditures.
Ongoing preparations for commercial launch leverage insights from provider dynamics and patient preferences, aiming for effective integration into expanding psychiatric treatment infrastructure.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit CMPS on AllInvestView.

Next Q1 2026